CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program

Core Insights - CROSSJECT has announced positive updates regarding its collaboration with ETON PHARMACEUTICALS for the ZENEO® adrenal insufficiency program, particularly focusing on the development of ZENEO® Hydrocortisone for the US and Canadian markets [3][4][5] Company Developments - CROSSJECT has developed a proprietary ready-to-use liquid formulation of hydrocortisone, which simplifies the administration process compared to existing products like PFIZER's Solu-Cortef® that require over ten steps for preparation [4] - ETON will commercialize the CROSSJECT Formulation, referred to as ET-800, and CROSSJECT will receive a high single-digit royalty on ETON's net sales [4][9] - ETON anticipates capturing a significant share of the hospital market for hydrocortisone injectables, estimated at $100 million, with future evaluations suggesting the market opportunity could exceed$200 million in the US alone [4][5][9] Future Outlook - ETON has confirmed its commitment to the ZENEO® Hydrocortisone project, with development and manufacturing milestones expected to commence from early 2026 [5][9] - CROSSJECT is also focused on accelerating the development of its products for adrenal insufficiency in the US and plans to leverage its experience to introduce innovative solutions in Europe and globally [6]